GlobeNewswire Clinical StudiesOriginal article
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
Data ReadoutpositiveMB-204Positive
AI Analysis
Summary
Marvel Biosciences reported positive preclinical data showing MB-204 reverses behavioral and cognitive deficits in a mouse model of Fragile X.
Clinical Trial Data
Phase
preclinical
Primary Endpoint
Met
Outcome Details
Preclinical data demonstrates MB-204 reverses behavioural and cognitive deficits in a mouse model of Fragile X
Importance:4/10
Sentiment:
0.70
preclinical datafragile xbehavioral deficitscognitive deficitsmouse model
Read the original article
Published by GlobeNewswire Clinical Studies on August 5, 2026 9:00 AM